Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 134.9% in January

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 273,000 shares, a growth of 134.9% from the December 31st total of 116,200 shares. Currently, 6.3% of the shares of the company are short sold. Based on an average trading volume of 242,400 shares, the short-interest ratio is currently 1.1 days.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on VVOS. Alliance Global Partners cut their target price on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th. Ascendiant Capital Markets reiterated a “buy” rating and issued a $6.60 price objective on shares of Vivos Therapeutics in a research note on Wednesday, November 20th.

Vivos Therapeutics Trading Up 1.0 %

Shares of VVOS traded up $0.04 during mid-day trading on Friday, hitting $3.97. 114,554 shares of the company’s stock were exchanged, compared to its average volume of 292,809. Vivos Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $7.74. The business’s 50 day moving average is $4.49 and its two-hundred day moving average is $3.30. The firm has a market capitalization of $23.38 million, a P/E ratio of -0.70 and a beta of 7.51.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.